undamentalytics Newsletter

Kalia Kumud: insider trades

Officer at Guardant Health, Inc. 3 open-market purchases and 15 sales not made under a pre-set plan, reported from August 19, 2022 to September 14, 2026.

Would copying Kalia Kumud’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 2 purchases have 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on June 14, 2023 into $15,405 by November 2, 2026, +13.7% a year. The copy held shares only 27% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $13,133, +8.4% a year (the S&P 500 held throughout made $18,073, +19.2% a year). Beta against the index was 0.26. Twelve months after each report, the average purchase was +51.3% against the S&P 500 (median +51.3%), and 50% beat it. Measured from the trade date, the insider’s own timing, the average was +55.5%. After their sales, the shares moved +46.3% against the index over 12 months on average (a negative figure means selling was the right call); 44% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$10.0k$20.0k 2023202420252026 $18.1k$15.4k$13.1k
Copying Kalia KumudS&P 500, same days investedS&P 500, held throughout $10,000 copying Kalia Kumud’s open-market purchases from June 14, 2023, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+13.7%
S&P 500, same days invested
+8.4% (held throughout +19.2%)
Time in shares
27%
Sharpe ratio (S&P 500)
0.41 (0.95)
Biggest drop (S&P 500)
−44% (−19%)
Market sensitivity (beta)
0.26
Purchases copied
2

Trade by trade

Kalia Kumud: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 3 +13.1% +1.9% 67% 3 — — Not enough years
Purchases, 6 months after the report 2 −1.1% −1.1% 50% 2 — — Not enough years
Purchases, 12 months after the report 2 +51.3% +51.3% 50% 2 — — Not enough years
Purchases, 12 months after the trade 2 +55.5% +55.5% 50% 2 — — Not enough years
Sales, 3 months after the report 14 +8.6% +4.8% 29% 5 0.75 0.50 No reliable evidence
Sales, 12 months after the report 9 +46.3% +5.8% 44% 4 1.02 0.38 No reliable evidence
Sales, 12 months after the trade 9 +45.4% +2.6% 44% 4 1.00 0.39 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Guardant Health, Inc. GH Chief Information Officer315August 19, 2022September 14, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
September 14, 2026September 11, 2026 GH Sale $632,200 not yetnot yetnot yet
June 30, 2026June 15, 2026 GH Purchase $78,456 +1.9%not yetnot yet
June 30, 2026June 10, 2026 GH Sale $157,164 +1.9%not yetnot yet
June 15, 2026June 11, 2026 GH Sale $445,160 +36.6%not yetnot yet
June 12, 2026June 10, 2026 GH Sale $652,050 +34.7%not yetnot yet
March 5, 2026March 4, 2026 GH Sale $3,812,742 +27.7%not yetnot yet
December 10, 2025December 8, 2025 GH Sale $209,200 −11.4%not yetnot yet
August 22, 2025August 21, 2025 GH Sale $123,520 +67.5%+155.7%+144.8%
June 5, 2025June 3, 2025 GH Sale $185,560 +16.6%+146.3%+162.1%
March 18, 2025March 17, 2025 GH Sale $151,060 +3.7%+68.2%+85.4%
November 19, 2024November 18, 2024 GH Sale $204,750 +30.5%+248.0%+234.0%
March 19, 2024March 18, 2024 GH Purchase $38,972 +59.8%+149.0%+144.9%
December 4, 2023December 1, 2023 GH Sale $152,946 −38.0%+5.9%+2.6%
September 13, 2023September 12, 2023 GH Sale $69,254 −12.6%−44.2%−48.4%
June 13, 2023June 9, 2023 GH Purchase $97,494 −22.5%−46.5%−33.9%
March 3, 2023March 3, 2023 GH Sale $207,480 +1.1%−66.9%−68.9%
November 17, 2022November 15, 2022 GH Sale $162,094 −43.7%−68.7%−71.1%
August 19, 2022August 17, 2022 GH Sale $102,780 +6.0%−27.8%−32.0%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Kalia Kumud traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.